Genetic test helps choose drug dosing for pancreas or colon cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests whether using a genetic test to guide medication doses works better than standard dosing for people with certain pancreas or colon cancers. It may help by tailoring treatment more precisely to your tumor’s genetic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed pancreas cancer (stage I–IV) or colorectal cancer (stage III–IV), and you are planning cancer treatment
- You are at least 18 years old
- Your daily functioning is limited at most a little (doctor rates it as 0–1)
- Your past treatment is allowed as long as it did not include irinotecan (a specific chemotherapy drug)
- You are able to take part in planned treatment (no major uncontrolled infection or serious unstable heart or ongoing psychiatric/social problems that would affect following the study)
- You are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a lab test to see how your tumor responds to different drugs, helping doctors choose the best treatment for you. It is for people with pancreatic cancer (PDAC) who are having surgery or a biopsy.
This study looks at whether using a detailed genetic test of your tumor can help pick the best first or second treatment for advanced lung, colon, breast, or bladder cancer. The goal is to see if this personalized approach helps people live longer.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
This trial tests whether a special blood test that detects cancer DNA can help doctors decide if you need additional chemotherapy after colorectal cancer surgery. The goal is to personalize treatment based on your individual risk rather than giving chemotherapy to everyone.
This trial tests a new combination of chemotherapy drugs for people whose pancreatic cancer has progressed after prior irinotecan treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This study is testing a new lab test called ChemoINTEL that may help predict how well your colorectal cancer will respond to common chemotherapy drugs. The goal is to see if this test can help doctors choose the most effective treatment for you.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.